TICKERNOMICS Sign up
Last Update: 2024-03-28 02:11:04
TransMedics Group Inc. ( TMDX ) https://www.transmedics.com
74.48USD
Sector:
Healthcare
Industry:
Medical Devices
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-0.28%
TMDX
SPY
32.74%
TMDX
87.32%
SPY
92.93%
TMDX
0.00%
SPY
224.41%
TMDX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
2315.05
1929.98
0.67
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-64.70
12.07
16.87
-1.14
0.00
-42.00
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-42.65
61.21
-20.26
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
-24.10
-25.06
0.00
Other Earnings and Cash Flow Stats:
TransMedics Group Inc. ( TMDX ) Net Income TTM ($MM) is -42.20
TransMedics Group Inc. ( TMDX ) Operating Income TTM ($MM) is -42.75
TransMedics Group Inc. ( TMDX ) Owners' Earnings Annual ($MM) is 72.11
TransMedics Group Inc. ( TMDX ) Current Price to Owners' Earnings ratio is 33.75
TransMedics Group Inc. ( TMDX ) EBITDA TTM ($MM) is -35.36
TransMedics Group Inc. ( TMDX ) EBITDA Margin is -20.26%
Capital Allocation:
TransMedics Group Inc. ( TMDX ) has paid 0.00 dividends per share and bought back -3.11417 million shares in the past 12 months
TransMedics Group Inc. ( TMDX ) has reduced its debt by 59.257 million USD in the last 12 months
Capital Structure:
TransMedics Group Inc. ( TMDX ) Interest-bearing Debt ($MM) as of last quarter is 9
TransMedics Group Inc. ( TMDX ) Annual Working Capital Investments ($MM) are -4
TransMedics Group Inc. ( TMDX ) Book Value ($MM) as of last quarter is 137
TransMedics Group Inc. ( TMDX ) Debt/Capital as of last quarter is 7%
Other Balance Sheet Stats:
TransMedics Group Inc. ( TMDX ) has 394 million in cash on hand as of last quarter
TransMedics Group Inc. ( TMDX ) has 54 million of liabilities due within 12 months, and long term debt 505 as of last quarter
TransMedics Group Inc. ( TMDX ) has 32 common shares outstanding as of last quarter
TransMedics Group Inc. ( TMDX ) has 0 million USD of preferred stock value
Academic Scores:
TransMedics Group Inc. ( TMDX ) Altman Z-Score is 2.26 as of last quarter
TransMedics Group Inc. ( TMDX ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
TransMedics Group Inc. ( TMDX ) largest shareholder is Fred Alger Management, LLC owning 1342915 shares at 100.02 ($MM) value
Stephen Gordon(an insider) Sold 1903 shares of TransMedics Group Inc. ( TMDX ) for the amount of $166759.89 on 2024-03-08
3.55% of TransMedics Group Inc. ( TMDX ) is held by insiders, and 94.47% is held by institutions
TransMedics Group Inc. ( TMDX ) went public on 2019-05-02
Other TransMedics Group Inc. ( TMDX ) financial metrics:
FCF:-44.55
Unlevered Free Cash Flow:-29.86
EPS:-3.11
Operating Margin:-42.65
Gross Profit Margin:61.21
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-74.12
Beta:0.00
Buffet's Owners Earnings:72.11
Price to Owner's Earnings:33.75
About TransMedics Group Inc. ( TMDX ) :
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.